life sciences

Life Sciences Transfer Pricing & Tax Disputes

CRA leverages cross-functional expertise to deliver best-in-class services to clients in the Life Sciences sector including strategic consulting, IP litigation, antitrust, and transfer pricing.  Life sciences companies have high-stakes transfer pricing issues due to their high-value IP and the risks embedded within the value chain.  CRA’s transfer pricing economists have assisted numerous pre-clinical biotech companies with their initial international expansion and IP planning; and commercial-phase companies design and document intercompany pricing policies relating to their physical goods supply chains.  CRA experts have provided expert witness reports in GlaxoSmithKline vs. Commissioner and in state transfer pricing disputes.


  • 01
    Global planning documentation for medical devices products company
    CRA was engaged by a mid-market global medical devices products company to perform a global transfer pricing planning study. The study involved the...
    View engagement
  • 02
    South American planning documentation for health products company
    CRA was engaged by a leading global health products company to perform a South American transfer pricing planning study. The study involved the benchmarking...
    View engagement
  • 03
    Cross-border biotech licensing of novel IP
    CRA provided economic analysis to a US-based biopharmaceutical company under audit by the French tax authority regarding the outbound license of novel IP from...
    View engagement

Meet our team

Subscribe to receive our latest Insights.